share_log

Invitae Co. (NYSE:NVTA) Receives Consensus Rating of "Hold" From Brokerages

Invitae Co. (NYSE:NVTA) Receives Consensus Rating of "Hold" From Brokerages

Invitae Co.纽约证券交易所代码:NVTA)获得经纪商的 “持有” 共识评级
Defense World ·  2022/11/15 16:41

Invitae Co. (NYSE:NVTA – Get Rating) has been assigned a consensus rating of "Hold" from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation and nine have issued a hold recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.33.

据市场评级公司报道,Invitae Co.(纽约证券交易所股票代码:NVTA-GET Rating)已被涵盖该公司的13家研究公司一致给予“持有”评级。4名研究分析师对该股给予了卖出建议,9名分析师对该公司提出了持有建议。在过去一年对该股进行评级的券商中,12个月目标价的平均水平为10.33美元。

Several equities analysts have recently commented on the company. Credit Suisse Group initiated coverage on Invitae in a research note on Wednesday, August 24th. They issued an "underperform" rating on the stock. Benchmark cut shares of Invitae from a "buy" rating to a "hold" rating in a research report on Tuesday, July 19th. Cowen lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 26th. Cowen cut shares of Invitae from an "outperform" rating to a "market perform" rating in a research report on Tuesday, July 26th. Finally, SVB Leerink boosted their target price on Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a research report on Wednesday, November 9th.

几位股票分析师最近对该公司发表了评论。瑞士信贷集团在8月24日星期三的一份研究报告中启动了对Invitae的报道。他们对该股给予了“表现不佳”的评级。在7月19日星期二的一份研究报告中,Benchmark将Invitae的股票评级从“买入”下调至“持有”。在7月26日周二的一份报告中,考恩将Invitae的股票评级从“跑赢大盘”下调至“市场表现”。在7月26日周二的一份研究报告中,考恩将Invitae的股票评级从“跑赢大盘”下调至“市场表现”。最后,SVB Leerink在11月9日(周三)的一份研究报告中将Invitae的目标价从2.50美元上调至3.00美元,并给予该公司“市场表现”评级。

Get
到达
Invitae
邀请函
alerts:
警报:

Invitae Price Performance

Invitae性价比

NVTA stock opened at $3.17 on Tuesday. Invitae has a 1 year low of $1.83 and a 1 year high of $22.35. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.42 and a quick ratio of 6.07. The firm has a market capitalization of $769.98 million, a PE ratio of -0.23 and a beta of 1.59. The business has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $3.04.

NVTA股价周二开盘报3.17美元。Invitae的一年低点为1.83美元,一年高位为22.35美元。该公司的负债权益比为4.12,流动比率为6.42,速动比率为6.07。该公司市值为7.6998亿美元,市盈率为-0.23,贝塔系数为1.59。该业务的50日简单移动均线切入位在2.67美元,200日简单移动均线切入位在3.04美元。

Invitae (NYSE:NVTA – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The medical research company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.17. Invitae had a negative net margin of 617.65% and a negative return on equity of 30.03%. The firm had revenue of $133.54 million for the quarter, compared to analysts' expectations of $132.80 million. Equities research analysts anticipate that Invitae will post -2.48 earnings per share for the current fiscal year.
Invitae(纽约证券交易所代码:NVTA-GET Rating)最近一次公布季度收益是在11月8日星期二。这家医学研究公司公布了本季度每股收益(0.42美元),比普遍预期的(0.59美元)高出0.17美元。Invitae的净利润率为负617.65%,净资产回报率为负30.03%。该公司本季度营收为1.3354亿美元,高于分析师预期的1.328亿美元。股票研究分析师预计,Invitae本财年的每股收益将达到2.48美元。

Institutional Investors Weigh In On Invitae

机构投资者在Invitae上发表看法

Several institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System lifted its position in Invitae by 4.6% in the first quarter. Arizona State Retirement System now owns 55,072 shares of the medical research company's stock valued at $439,000 after acquiring an additional 2,425 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Invitae by 25.1% in the 2nd quarter. Mackenzie Financial Corp now owns 13,948 shares of the medical research company's stock valued at $34,000 after purchasing an additional 2,795 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Invitae by 9.7% in the 1st quarter. Private Advisor Group LLC now owns 32,282 shares of the medical research company's stock valued at $258,000 after purchasing an additional 2,845 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Invitae by 42.1% in the 1st quarter. SG Americas Securities LLC now owns 10,341 shares of the medical research company's stock valued at $82,000 after purchasing an additional 3,062 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Invitae by 5.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 63,738 shares of the medical research company's stock worth $508,000 after buying an additional 3,096 shares during the last quarter. Hedge funds and other institutional investors own 88.27% of the company's stock.

几家机构投资者最近增持或减持了该公司的股份。亚利桑那州退休制度在第一季度将其在Invitae的头寸提高了4.6%。亚利桑那州退休系统现在拥有55,072股这家医疗研究公司的股票,价值439,000美元,在上个季度额外购买了2,425股。Mackenzie Financial Corp在第二季度增持了Invitae股票25.1%。麦肯锡金融公司(Mackenzie Financial Corp)目前持有这家医疗研究公司13,948股票,价值34,000美元,此前该公司在上个季度又购买了2,795股票。Private Advisor Group LLC在第一季度增持了9.7%的Invitae股票。Private Advisor Group LLC现在拥有这家医疗研究公司32,282股股票,价值258,000美元,上个季度又购买了2,845股。SG America Securities LLC在第一季度将其在Invitae股票的头寸增加了42.1%。在此期间,SG America Securities LLC又购买了3,062股,目前持有这家医疗研究公司10,341股股票,价值82,000美元。最后,Envestnet Asset Management Inc.在第一季度增持了Invitae 5.1%的股份。Envestnet Asset Management Inc.现在持有这家医疗研究公司63,738股股票,价值508,000美元,上个季度又购买了3,096股。对冲基金和其他机构投资者持有该公司88.27%的股票。

About Invitae

关于Invitae

(Get Rating)

(获取评级)

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.

Invitae公司是一家医学遗传学公司,将遗传信息整合到主流医学中,以改善美国、加拿大和国际上人们的医疗保健。该公司提供各种临床领域的基因测试,包括遗传癌、心脏病学、神经病学、儿科、肿瘤学、代谢疾病和罕见疾病;数字健康解决方案;以及健康数据服务。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Invitae (NVTA)
  • Wayfair Still Has Its Fair Share of Issues
  • Take Two Interactive Software Stock is Taking One Step Back
  • This Mid-Cap Tech Stock Embodies Diversified Growth
  • Why did NIO take a $581.11 million loss last quarter?
  • Is It Time To Take A Ride With Joby Aviation's EV Innovations?
  • 免费获取StockNews.com关于Invitae的研究报告(NVTA)
  • WayFair仍有其公平份额的问题
  • 交互软件股票后退一步
  • 这只中型科技股体现了多元化的增长
  • 为什么上个季度蔚来亏损5.811亿美元?
  • 是时候与Joby Aviation的电动汽车创新一起兜风了吗?

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.

接受《邀请日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Invitae和相关公司的最新新闻和分析师评级的每日简要摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发